Fig. 3.

Comparisons of the levels of plasma SP-A, plasma sRAGE, sputum MPO, and sputum NGAL in ACOS patients with different disease severity and control group before and after treatment.

ACOS = asthma-chronic obstructive pulmonary disease overlap syndrome, A = mild ACOS group, B = moderate ACOS group, C = severe ACOS group, D = extremely severe ACOS group, MPO = sputum myeloperoxidase, NGAL = sputum neutrophil gelatinase-associated lipocalin; sRAGE = plasma soluble receptor for advanced glycation end products, SP-A = plasma surfactant protein A, Before = before the 6-month treatment, After = after the 6-month treatment.

^*P < 0.05, compared with the control group before treatment; ^†P < 0.05, compared with the control group after treatment; ^‡P < 0.05, compared with the mild ACOS, moderate ACOS, severe ACOS, extremely severe ACOS, and control groups.